Use of a Colorectal Cancer Screening Decision Support Tool in Primary Care
Launched by MASSACHUSETTS GENERAL HOSPITAL · Oct 2, 2024
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a special tool that helps people make decisions about colorectal cancer (CRC) screening can increase the number of patients who actually get screened. The tool is designed for adults aged 45 to 75 who are at average risk for CRC and are overdue for screening. By using this decision support tool before their primary care visits, the goal is to help these patients understand their screening options and encourage them to choose and complete their preferred method of screening.
To participate, you should be between 45 and 75 years old, have an annual visit scheduled with one of the participating practices, and be overdue for CRC screening. However, if you are at high risk for colorectal cancer, you won’t be eligible for this trial. If you decide to join, you can expect to use the decision support tool as part of a questionnaire during your visit, which will help you make an informed choice about CRC screening. The study is currently recruiting participants, and your involvement could help improve screening rates for colorectal cancer in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 45-75 overdue for CRC screening at average risk of CRC have an annual visit scheduled with participating practices
- Exclusion Criteria:
- • high risk of CRC
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Karen Blumenthal, MD
Principal Investigator
Massachusetts General Hospital
Karen Sepucha, PhD
Study Director
MGH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported